These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 19702545)

  • 21. Impact of early cyclosporin average blood concentration on early kidney transplant failure.
    Senel MF; Van Buren CT; Welsh M; Kahan BD
    Transpl Int; 1998; 11(1):46-52. PubMed ID: 9503554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of appropriate blood level in continuous intravenous infusion from trough concentrations after oral administration based on area under trough level in tacrolimus and cyclosporine therapy.
    Nakamura Y; Takeuchi H; Okuyama K; Akashi T; Jojima Y; Konno O; Akashi I; Hama K; Iwahori T; Ashizawa T; Hirano T; Oka K; Matsuno N; Nagao T
    Transplant Proc; 2005 May; 37(4):1725-7. PubMed ID: 15919445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients.
    Lam H; Jeffery J; Sitar DS; Aoki FY
    Ther Drug Monit; 2011 Dec; 33(6):699-704. PubMed ID: 22105586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced oral cyclosporine absorption with water-soluble vitamin E early after liver transplantation.
    Pan SH; Lopez RR; Sher LS; Hoffman AL; Podesta LG; Makowka L; Rosenthal P
    Pharmacotherapy; 1996; 16(1):59-65. PubMed ID: 8700793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
    Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
    Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modifications in cyclosporine (CsA) microemulsion blood concentrations by olestra.
    Terrill CJ; Lill J; Somerville KT; Sherbotie JR
    J Ren Nutr; 2003 Jan; 13(1):26-30. PubMed ID: 12563620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isoniazid does not affect bioavailability of cyclosporine in renal transplant recipients.
    Sud K; Muthukumar T; Singh B; Garg SK; Kohli HS; Jha V; Gupta KL; Sakhuja V
    Methods Find Exp Clin Pharmacol; 2000 Oct; 22(8):647-9. PubMed ID: 11256238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A 50% reduction in cyclosporine exposure in stable renal transplant recipients: renal function benefits.
    Etienne I; Toupance O; Bénichou J; Thierry A; Al Najjar A; Hurault de Ligny B; Le Meur Y; Westeel PF; Marquet P; François A; Hellot MF; Godin M
    Nephrol Dial Transplant; 2010 Sep; 25(9):3096-106. PubMed ID: 20299336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression.
    Filler G; Zimmering M; Mai I
    Pediatr Nephrol; 2000 Feb; 14(2):100-4. PubMed ID: 10684356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. C2 monitoring and absorption profiling of cyclosporine for optimization of immunosuppressive therapy in pediatric renal transplant recipients.
    Weber LT; Shipkova M; Armstrong VW; Mehls O; Oellerich M; Tönshoff B;
    Transplant Proc; 2003 Sep; 35(6):2128-30. PubMed ID: 14529863
    [No Abstract]   [Full Text] [Related]  

  • 31. Reduced variability of neoral pharmacokinetic studies in pediatric renal transplantation.
    Meier-Kriesche HU; Swinford R; Kahan BD; Brannan P; Portman RJ
    Pediatr Nephrol; 2000 Nov; 15(1-2):2-6. PubMed ID: 11095000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Mycophenolic acid concentration profiles may select recipients with high-risk of acute rejection in renal transplant recipients].
    Kuriata-Kordek M; Boratyńska M; Urbaniak J; Woźniak M; Patrzałek D; Szyber P; Klinger M
    Pol Merkur Lekarski; 2006 Aug; 21(122):161-3; discussion 164. PubMed ID: 17144102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of active infection on cytochrome P450-mediated metabolism of cyclosporine in renal transplant patients.
    Hegazy SK; Adam AG; Hamdy NA; Khalafallah NM
    Transpl Infect Dis; 2015 Jun; 17(3):350-60. PubMed ID: 25702620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The value of C2 monitoring in stable renal allograft recipients on maintenance immunosuppression.
    Einecke G; Mai I; Fritsche L; Slowinski T; Waiser J; Neumayer HH; Budde K
    Nephrol Dial Transplant; 2004 Jan; 19(1):215-22. PubMed ID: 14671060
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Graft function based on two hours peak level monitoring of cyclosporine A during the first six months of renal transplantation.
    Hami M; Naghibi M; Mojahedi MJ; Sharifipour F; Shakeri MT
    Saudi J Kidney Dis Transpl; 2012 Nov; 23(6):1169-74. PubMed ID: 23168844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Excellent results with high-dose mizoribine combined with cyclosporine, corticosteroid, and basiliximab in renal transplant recipients: multicenter study in Japan.
    Nishimura K; Uchida K; Yuzawa K; Fukuda Y; Ichikawa Y; Akioka K; Fujisawa M; Sugitani A; Ito S; Nakatani T; Horimi T; Yoshimura N
    Transplant Proc; 2012 Jan; 44(1):147-9. PubMed ID: 22310601
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit.
    de Jonge H; Vanhove T; de Loor H; Verbeke K; Kuypers DR
    Br J Clin Pharmacol; 2015 Sep; 80(3):548-59. PubMed ID: 26114223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tacrolimus versus cyclosporin A: a comparative study on rat renal allograft survival.
    Jiang H; Sakuma S; Fujii Y; Akiyama Y; Ogawa T; Tamura K; Kobayashi M; Fujitsu T
    Transpl Int; 1999; 12(2):92-9. PubMed ID: 10363590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclosporine peak concentration in relation to the four-hour absorption phase in pediatric renal graft recipients.
    Wigger M; Drückler E; Muscheites J; Stolpe HJ; Kundt G; Wacke R
    Transplant Proc; 2001; 33(7-8):3126-7. PubMed ID: 11750344
    [No Abstract]   [Full Text] [Related]  

  • 40. A nomogram for predicting optimal dosage of cyclosporine in renal transplant patients: taking physiological factors into consideration for regimen during immunosuppressive therapy.
    Shibata N; Hoshino N; Minouchi T; Yamaji A
    Biol Pharm Bull; 1995 Oct; 18(10):1423-9. PubMed ID: 8593449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.